Search Results
65 Results for 'Oncology'
PAGE 3 OF 3
Technology
Novel Small Molecule SIRT6 Activators/Inhibitors
The epigenetic modifier SIRT6 is of the sirtuin class of proteins. In transgenic mice, increased SIRT6 expression lowers LDL and triglyceride levels, improves glucose tolerance and increases mitochond...
Learn More
Learn More
John Denu, Weiping Tang | P160306US01
Technology
Methods and Compositions for Treating Prostate Cancer Using DNA Vaccines
Prostate cancer is a significant health risk for men over the age of 50 and currently is a pervasive health threat with as many as 200,000 new cases diagnosed each year in the US alone. At present, t...
Learn More
Learn More
Douglas McNeel, Brian Olson | P05235US
Technology
Combinatorial Androgen Deprivation With An Androgen Receptor Vaccine
The androgen receptor (AR) is a steroid hormone receptor that plays a crucial role in the development of normal prostate tissue, as well as in the progression of prostate cancer. Patients with metasta...
Learn More
Learn More
Douglas McNeel, Brian Olson | P160108US02
Technology
Novel Analogs of Podophyllotoxin May Treat Cancer and Viral Infections
Podophyllotoxin is a natural product derived from a plant. Although two clinically useful glycosylated analogs have been developed for treating cancer, podophyllotoxin is difficult to synthesize, hind...
Learn More
Learn More
Jon Thorson, James Watson, Jr. | P08343US
Technology
Inhibiting Metadherin/SND1 Interaction to Treat Cancer
Metadherin (MTDH; also called AEG1 or LYRIC) is a pro-metastasis gene implicated in many types of cancer. The gene is overexpressed in more than 40 percent of primary tumors and is linked to breast ca...
Learn More
Learn More
Yongna Xing, Liling Wan, Yibin Kang, Feng Guo | P140424US02
Technology
Analogs of Diptoindonesin G for Breast Cancer Drug Development
The natural product diptoindonesin G (Dip G) was first isolated in 2009 from the tree bark of Hopea mengarawan. It has shown antiproliferation effects in murine leukemia as well as immunosuppressant a...
Learn More
Learn More
Wei Xu, Weiping Tang, Jitian Liu, Jill Kolesar | P170010US02
Technology
Increasing Red Blood Cell Production
Maintaining an adequate supply of oxygen to tissue is necessary for survival. The oxygen-carrying capacity of blood is governed by the concentration of red blood cells (erythrocytes). It is critical t...
Learn More
Learn More
Emery Bresnick, Yoon A Kang, Skye McIver | P130326US02
Technology
Treating Iron Overload with Block Copolymers
Iron overload or hemochromatosis is a disease marked by an accumulation of iron in the blood. It typically occurs in subjects (e.g., anemia patients) receiving chronic infusions of red blood cells. Th...
Learn More
Learn More
May Xiong, Zhi Liu, Yan Wang | P140395US02
Technology
Provoking Anti-Tumor Immune Response with Rhamnose
One promising approach to cancer treatment is to leverage the immune system. Specifically, tumors can be ‘tagged’ with foreign antigens that attract the body’s defensive antibodies. The antibodi...
Learn More
Learn More
Laura Kiessling, Rachael Sheridan, Jonathan Hudon | P120290US02
Technology
Protecting Ovaries from Chemotherapy Damage Using Proteasome Inhibitors
Primary ovary insufficiency (POI) caused by chemotherapy treatment is experienced by many cancer survivors, including up to 40 percent of reproductive-age breast cancer survivors and eight percent of ...
Learn More
Learn More
Sana Salih, Elon Roti Roti | P130111US02
Technology
Vitamin D Analogs “1D-QM” and “1D-QMS” for Cancer, Bone Disease Therapy
The hormonally active form of vitamin D, known as calcitriol or 1,25 dihydroxyvitamin D3, has shown promise for treating diseases ranging from osteoporosis to cancer to psoriasis. However, the hormone...
Learn More
Learn More
Hector DeLuca, Lori Plum, Rafal Sicinski, Izabela Sibilska-Kaminski | P120085US02
Technology
Vitamin D Analogs for Treating Bone Cancers and Diseases
The hormonally active form of vitamin D, known as calcitriol or 1,25 dihydroxyvitamin D3, has shown promise for treating diseases ranging from osteoporosis to cancer to psoriasis. However, the hormone...
Learn More
Learn More
Hector DeLuca, Margaret Clagett-Dame, Lori Plum, Izabela Sibilska-Kaminski, Rafal Sicinski | P100358US03
Technology
Prostate Cancer and Melanoma Screening
Almost 200,000 men in the United States develop prostate cancer each year. More than 60,000 people develop melanoma. Early diagnosis is key to survival because the best treatment and prognosis for the...
Learn More
Learn More
Douglas McNeel, Edward Dunphy, Jason Dubovsky, Luke Hoeppner | P06004US
Technology
Cytotoxic Ribonuclease Variants
Ribonucleases are enzymes that catalyze the degradation of RNA. Levels of RNase activity are controlled in vivo by a ribonuclease inhibitor (RI), which binds strongly to an RNase to completely inhibit...
Learn More
Learn More
Ronald Raines, George Phillips, R. Jeremy Johnson, Jason McCoy | P05341US
Technology
Cytotoxic Ribonuclease Variants
Ribonucleases are enzymes that catalyze the degradation of RNA. Levels of RNase activity are controlled in vivo by a ribonuclease inhibitor (RI), which binds strongly to an RNase to completely inhibit...
Learn More
Learn More
Ronald Raines, Julie Mitchell, Thomas Rutkoski | P04427US